New clinical trial to investigate affects of CBD on Parkinson’s related psychosis

A pioneering clinical trial is set to investigate the use of cannabidiol (CBD) in people with Parkinson’s-related psychosis. Parkinson’s UK will be partnering with scientists at King’s College London in the first large-scale trial which aims to provide preliminary evidence for the safety and efficacy of CBD to alleviate the symptoms of Parkinson’s-related psychosis, characterised by hallucinations and delusions.

Continue Reading

Novartis treatment achieves positive results in possible new indication

Novartis announced positive results from its Cosentyx focused PREVENT trial, advancing the drug in potential new indication for patients with axial spondyloarthritis. The phase III study met its 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), showing a considerable and clinically meaningful reduction in disease activity. Novartis has also submitted

Continue Reading

CPIA Report: Human Resources and Talent

Our latest CPIA report features analysis and UK and EU vacancy data in the “Human Resources and Talent” sector. Clinical Professionals Group CEO, Yvette Cleland comments: Life sciences cost per hire will continue to rise at a rate of 7% per annually, talent pools continue to constrict and 85% of jobs that will exist in

Continue Reading

1,500 GSK Contractors written to by HMRC in reference to “disguised employment”

IR35 rules are designed to stop tax avoidance by workers who provide services to clients via a limited company rather than as employees.  A contractor operating through a Limited company but otherwise practically operating as an employee is considered to be a “disguised employee”. HMRC stated there is evidence that contractors in the pharmaceutical industry

Continue Reading

Janssen’s results show Tremfya beats Cosentyx in late stage psoriasis study

Johnson & Johnson’s Janssen has announced their results from Phase III ECLIPSE study, which show superior long-term efficacy of Tremfya (guselkumab) compared with Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis. The data, which was published in The Lancet, showed a significantly higher proportion of Tremfya patients achieved a PASI 90 response at Week

Continue Reading

Astellas announce first dosing of patient in late-stage menopause trial

Astellas Pharma has announced the initiation and dosing of the first patient in their SKYLIGHT1 Phase III pivotal trial for fezolinetant. The investigational oral, non-hormonal compound is being studied for the treatment of moderate-to-severe menopause related vasomotor symptoms (VMS), such as hot flashes and night sweats. The first trials of the programme will evaluate the efficacy

Continue Reading

Health Economics and Market Access CPIA Report

The latest CPIA report features analysis and UK and EU vacancy data in the “Health Economics and Market Access” sector. Clinical Professionals Group CEO, Yvette Cleland comments: Development of a nation is crucially connected with the condition of the health of its population. Health is now accepted as an important indication of the developing economy

Continue Reading

Clinical Professionals Sponsors BIA Webinar Series

The Clinical Professionals Group are delighted to be media sponsors for a webinar series, created by the BIA’s Science and Innovation Advisory Committee (SIAC) called “Bench to Bedside”. It features 4 informative episodes that includes content put forward by industry professionals that look to explore the drug discovery process from innovation to delivery. The series

Continue Reading